Statement, May 2019

South Centre Statement on Access to Biosimilars/Biogeneric Medicines at the WHA 72

The revision of the guidelines on similar therapeutic products mandated by Resolution WHA67.21 is crucial for promoting the availability of and access to biosimilars. The reduction in prices ensuing from the introduction of these products has become essential to address public health needs in developed and developing countries. The WHO Document A72/59 under consideration by the WHA 72 (agenda item 21.3) states in paragraph 80 that “WHO expert committees have approved guidance on (…) biotherapeutics, including an update of the 2009 similar biotherapeutic products guidelines”. This statement is not accurate, as the guidelines were not updated as mandated by Resolution WHA67.21. Below is the South Centre statement in relation to this issue.

Download the statement below:

South Centre Statement on Access to Biosimilars/Biogeneric Medicines at the WHA 72


This article was tagged: , , , , ,
0

Your Cart